Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.

Official Title

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours

Keywords

Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma, Leucovorin, Fluorouracil, Oxaliplatin, BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)

Eligibility

Locations

  • University of California, Los Angeles accepting new patients
    Santa Monica California 90095 United States
  • Cross Cancer Institue accepting new patients
    Edmonton Alberta Canada

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bold Therapeutics, Inc.
ID
NCT04421820
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 220 study participants
Last Updated